Biotech sci­en­tist/en­tre­pre­neur Saurabh Sa­ha makes an un­usu­al re­turn to the arms of a big — and ex­ces­sive­ly dis­creet — R&D group

Over the past few years we’ve seen a grow­ing ex­o­dus of R&D ex­perts out of big bio­phar­ma groups and in­to the rapid­ly grow­ing ranks of biotech star­tups. Now, one of the biggest play­ers in the on­col­o­gy field is get­ting at least one suc­cess­ful biotech sci­en­tist and en­tre­pre­neur to make an un­usu­al re­turn trip and come back in­to the fold of a ma­jor re­search or­ga­ni­za­tion.

Saurabh Sa­ha

This morn­ing Bris­tol-My­ers Squibb $BMY put out word that the com­pa­ny had hired Saurabh Sa­ha to run the trans­la­tion sci­ence group for the com­pa­ny, which is re­spon­si­ble for triag­ing pre­clin­i­cal work of in­ter­est and steer­ing the most promis­ing pro­grams to­ward the clin­ic.

Sa­ha — a 40-year-old Johns Hop­kins grad, where he worked in Bert Vo­gel­stein’s lab — once up­on a time la­bored in­side No­var­tis’ glob­al ops, be­fore leav­ing for a string of new jobs in biotech. Nine years ago he set up a trans­la­tion­al re­search and de­vel­op­ment or­ga­ni­za­tion called Bio­Med Val­ley Dis­cov­er­ies. Then his role as a ven­ture part­ner at the pro­lif­ic At­las Ven­ture led him to be­come chief med­ical of­fi­cer at Syn­log­ic, fol­lowed by a brief but wild­ly suc­cess­ful stint as CEO of Delinia.

Back at the be­gin­ning of this year Cel­gene stepped up with a $775 mil­lion deal to ac­quire Delinia — with $300 mil­lion of that in cash — just four months af­ter Sa­ha lined up a $35 mil­lion round to back a pre­clin­i­cal au­toim­mune drug that showed promise in con­trol­ling reg­u­la­to­ry T cells, restor­ing im­mune tol­er­ance and home­osta­sis.

Odd­ly, Bris­tol-My­ers has de­cid­ed to keep Sa­ha un­der wraps for this an­nounce­ment, not al­low­ing in­ter­views. That’s too bad, as com­pa­nies like Bris­tol-My­ers could use all the fresh, in­tel­li­gent faces it can get to per­suade in­vestors that there’s rea­son to be­lieve new stuff is com­ing along to whip up some ex­cite­ment.

As big bio­phar­ma of­fers re­peat­ed ev­i­dence of the kind of cash-con­strained, slow mov­ing en­vi­ron­ments that re­searchers have chafed against, high-risk biotechs with op­por­tu­ni­ty for rapid re­wards and cash wind­falls have of­fered a com­pelling bea­con for some high pro­file ex­ecs. What­ev­er Sa­ha’s rea­sons, any­thing he says that might per­suade sci­en­tists to re­con­sid­er that could on­ly ben­e­fit an in­dus­try where the trends have so far point­ed in on­ly one di­rec­tion.

That’s par­tic­u­lar­ly true for the trans­la­tion­al side of the busi­ness.

Sa­ha is stay­ing in the Boston area, where Bris­tol-My­ers is build­ing a new R&D cen­ter.

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

2021 saw a record $600B in healthcare M&A activity. In 2022, there is an anticipated slowdown in activity, however, M&A prospects remain strong in the medium to long-term. What are future growth drivers for the healthcare sector? Where might we see innovations that drive M&A? RBC’s Andrew Callaway, Global Head, Healthcare Investment Banking discusses with Vito Sperduto, Global Co-Head, M&A.

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Abortion-rights protesters regroup and protest following Supreme Court's decision to overturn Roe v. Wade. (AP Photo/Gemunu Amarasinghe)

Fol­low­ing SCO­TUS de­ci­sion to over­turn abor­tion pro­tec­tions, AG Gar­land says states can't ban the abor­tion pill

Following the Supreme Court’s historic decision on Friday to overturn Americans’ constitutional right to an abortion after almost 50 years, Attorney General Merrick Garland sought to somewhat reassure women that states will not be able to ban the prescription drug sometimes used for abortions.

Following the decision, the New England Journal of Medicine also published an editorial strongly condemning the reversal, saying it “serves American families poorly, putting their health, safety, finances, and futures at risk.”

Joe Papa (Ryan Remiorz/The Canadian Press via AP, File)

Joe Pa­pa re­signs as chair of Bausch Health as bil­lion­aire John Paul­son takes over

Joe Papa, chair of Bausch Health, officially resigned on Thursday and the board appointed billionaire hedge fund manager John Paulson as the new chair, effective immediately.

The specialty pharma company sought to make clear that Papa’s abrupt departure “was not due to any dispute or disagreement with the Company, its management or the Board on any matter relating to the Company’s operations, policies or practices.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

De­spite a slow start to the year for deals, PwC pre­dicts a flur­ry of ac­tiv­i­ty com­ing up

Despite whispers of a busy year for M&A, deal activity in the pharma space is actually down 30% on a semi-annualized basis, according to PwC’s latest report on deal activity. But don’t rule out larger deals in the second half of the year, the consultants said.

PwC pharmaceutical and life sciences consulting solutions leader Glenn Hunzinger expects to see Big Pharma companies picking up earlier stage companies to try and fill pipeline gaps ahead of a slew of big patent cliffs. Though a bear market continues to maul the biotech sector, Hunzinger said recent deals indicate that pharma companies are still paying above current trading prices.

Joe Wiley, Amryt Pharma CEO

Am­ryt Phar­ma sub­mits a for­mal dis­pute res­o­lu­tion to the FDA over re­ject­ed skin dis­ease drug

The story of Amryt Pharma’s candidate for the genetic skin condition epidermolysis bullosa, or EB, will soon enter another chapter.

After the Irish drugmaker’s candidate, dubbed Oleogel-S10 and marketed as Filsuvez, was handed a CRL earlier this year, the company announced in a press release that it plans to submit a formal dispute resolution request for the company’s NDA for Oleogel-S10.

Sen. Thom Tillis (R-NC) (J. Scott Applewhite/AP Images)

Phar­ma-friend­ly sen­a­tor calls on FDA for a third time to show patent pro­tec­tions should­n't be blamed for high drug prices

North Carolina Republican Sen. Thom Tillis made a name for himself in the 2020 election cycle as the darling of the pharma industry, accepting hundreds of thousands in campaign contributions, even from the likes of Pfizer CEO Albert Bourla.

Those contributions have led Tillis to attempt to re-write patent laws in pharma’s favor, a move which failed to gain steam in 2019, and request for a third time since January that the FDA should help stop “the false narrative that patent protections are to blame for high drug prices.”

EMA signs off on 3 drugs re­cent­ly re­ject­ed by FDA, in­clud­ing Bio­Mar­in's new he­mo­phil­ia gene ther­a­py

The EMA’s human medicines committee on Friday recommended three new drugs for approval or conditional approval, even as their US counterparts have rejected these three for various reasons.

In a major move, CHMP offered a thumbs-up to a conditional marketing authorization for the first gene therapy to treat severe hemophilia A, although the agency cautioned that it’s so far unknown how long the effects of infusion will last.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.

Sanofi, GSK tout 72% Omi­cron ef­fi­ca­cy in PhI­II tri­al of next-gen, bi­va­lent shot — with an eye to year-end roll­out

Sometimes, being late can give you an advantage.

That’s what Sanofi and GSK are trying to say as the Big Pharma partners report positive results from a late-stage trial of their next-gen bivalent Covid-19 vaccine, which was designed to protect against both the original strain of the SARS-CoV-2 virus and the Beta variant. Specifically, against Omicron, they note, the vaccine delivered 72% efficacy in all adults and 93.2% in those previously infected.